Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas

Clinical Cancer Research

Volumn 3, Issue 10, 1997, Pages 1889-1897

  Chi, Sung Gil ^a,b   DeVere White, Ralph W ^a   Muenzer, Jared T ^a   Gumerlock, Paul H ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kyung Hee University Hospital   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; DNA DETERMINATION; DOWN REGULATION; GENE DELETION; GENE LOCATION; HUMAN; HUMAN CELL; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; TRANSCRIPTION REGULATION;

ADENOCARCINOMA; ANIMALS; AZACITIDINE; BLOTTING, WESTERN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; GENES, RETINOBLASTOMA; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0030792699     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Fountain, J. W., Karayiorgou, M., Ernstoff, M. S., Kirkwood, J. M., Vlock, D. R., Titus-Ernstoff, L., Bouchard, B., Vijaysaradhi, S., Houghton, A. N., Lahti, J., Kidd, V. J., Housman, D. E., and Dracopoli, N. C. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl. Acad. Sci. USA, 89: 10557-10561, 1992.
2. Cannon-Albright, L. A., Goldgar, D. E., Meyer, L. J., Lewis, C. M., Anderson, D. E., Fountain, J. W., Hegi, M. E., Wiseman, R. W., Petty, E. M., Bale, A. E., Olopade, O. I., Diaz, M. O., Kwiatkowski, D. J., Piepkon, M. W., Zone, J. J., and Skolnick, M. H. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science (Washington DC), 258: 1148-1152, 1992.
3. Kamb, A., Gruis, N., Weaver-Feldhaus, J., Jiu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
4. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
5. Koh, J., Enders, G. H., David Dynlacht, B., and Harlow, E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (Lond.), 375: 506-510, 1995.
6. INK4 function. Nat. Genet., 10: 114-116, 1995.
7. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. Retinoblastoma protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375: 503-506, 1995.
8. INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045-11049, 1994.
9. INK4/MTS1 tumour suppressor gene product. EMBO J., 14: 503-511, 1995.
10. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54: 6078-6082, 1994.
11. INK4, the product of the putative tumor suppressor gene MTS1. Oncogene, 9: 3475-3482, 1994.
12. Spruck, C. H., III, Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. R., Lin, M-F., Gonzales, F., Tsai, Y. C., and Jones, P. A. p16 gene in uncultured tumors. Nature (Lond.), 370: 183-184, 1994.
13. Caldas, C., Fahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., and Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 8: 27-32, 1994.
14. Mon, T., Miura, K., Aoki, T., Nishihira, T., Mori, S., and Nakamura, Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54: 3396-3397, 1994.
15. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
16. Mickey, D. D., Stone, K. R., Wunderli, H., Mickey, G. H., Vollmer, R. T., and Paulson, D. F. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res., 37: 4049-4058, 1977.
17. Kaighn, M. E., Naayan, S., Ohnuki, Y., Lechner, J. F., and Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol., 17: 16-23, 1979.
18. Iizumi, T., Yazaki, T., Kanoh, S., Kondo, I., and Koiso, K. Establishment of a new prostatic carcinoma cell line (TSU-Pr1). J. Urol., 137: 1304-1306, 1987.
19. Pretlow, T. G., Wolman, S. R., Micale, M. A., Pelly, R. J., Kursh., E. D., Resnick, M. I., Bodner, D. R., Jacobberger, J. W., Delmore, C. M., Giaconia, J. M., and Pretlow, T. P. Xenografts of primary human prostatic carcinoma. J. Natl. Cancer Inst., 85: 394-398, 1993.
20. Gumerlock, P. H., Poonamallee, U. R., Meyers, F. J., and deVere White, R. W. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res., 51: 1632-1637, 1991.
21. Meyers, F. J., Gumerlock, P. H., Kawasaki, E. S., Wang, A. M., deVere White, R. W., and Erlich, H. A. Human leukocyte antigen II, interleukin-6, and interleukin-6 receptor expression determined by polymerase chain reaction. Cancer (Phila.), 67: 2087-2095, 1991.
22. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
23. Gumerlock, P. H., Meyers, F. J., Kokoris, S. P., Wong, G., McCormick, F. P., and deVere White, R. W. RAS enzyme-linked immunoblot assay discriminates p21 species: a technique to dissect gene family expression. Anal. Biochem., 180: 158-168 1989.
24. Towbin, H., Staehlin, T., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4350-4354, 1979.
25. Chi, S-G., deVere White, R. W., Meyers, F. J., Siders, D., Lee, F., and Gumerlock, P. H. p53 in prostate: frequent expressed transition mutations. J. Natl. Cancer Inst., 86: 926-933, 1994.
26. Saunders, K. A., Madewell, B. R., Oreffo, V. I. C., Kraegel, S. A., and Gumerlock, P. H. Nucleotide sequence of canine c-N-ras: codons 1 to 71. Am. J. Vet. Res., 53: 600-603, 1992.
27. Stranks, G., Height, S. E., Mitchell, P., Jadayel, D., Yuille, M. A. R., De Lord, C., Clutterbuck, R. D., Treleaven, J. G., Powles, R. L., Nacheva, E., Oscier, D. G., Karpas, A., Lenoir, G. M., Smith, S. D., Millar, J. L., Catovsky, D., and Dyer, M. J. S. Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood, 85: 893-901, 1995.
28. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
29. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res., 55: 1448-1451, 1995.
30. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene, 9: 3375-3378, 1994.
31. Herman, J. G., Merio, A., Mao, L., Lapidus, R. G., Issa, J-P. J., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
32. INK4 expression in primary lung cancers and cell lines. Cancer Res., 55: 505-509, 1995.
33. Bookstein, R., Shew, J-Y., Chen, P-L., Scully, P., and Lee, W-H. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science (Washington DC), 247: 712-715, 1990.
34. Beltinger, C. P., White, P. S., Sulman, E. P., Maris, J. M., and Brodeur, G. M. No CDKN2 mutations in neuroblastomas. Cancer Res., 55: 2053-2055, 1995.
35. Liu, Q., Neuhausen, S., McClure, M., Frye, C., Weaver-Feldhaus, J., Gruis, N. A., Eddington, K., Allalunis-Turner, M. J., Skolnick, M. H., Fujimura, F. K., and Kamb, A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 10: 1061-1067, 1995.
36. Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H., Parry, D., Peters, G., and Kamb, A. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res., 55: 2988-2994, 1995.
37. INK4A transcript. Cancer Res., 55: 2995-2997, 1995.
38. Mack, P. C., Chi, S. C., Meyers, F. J., Stewart, S. L., deVere White, R. W., and Gumerlock, P. H. Increased tumor suppressor gene RB1 abnormalities in human prostate cancer following combined androgen blockade. Prostate, in press, 1997.
39. Visikorpi, T., Kallioniemi, A. H., Syvanen, A. C., Hyytinen, E. R., Karhu, R., and Tammela, T. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res., 55: 342-347, 1995.
40. Tamimi, Y., Bringuier, P. P., Smit, F., van Bokhoven, A., Debruyne, F. M, J., and Schalken, J. A. p16 mutations/deletions are not frequent events in prostate cancer. Br. J. Cancer, 74: 120-122, 1996.
41. Chen, W., Weghorst, C., Sabourin C., Wang, Y., Wang, D., Bostwick, D., and Stoner, G. Absence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis (Lond.), 17: 2603-2607, 1996.
42. Sun, Y., Hildesheim, A., Lanier, A. E. P., Cao, Y., Yao, K-T., Raab-Traub, N., and Yang, C-S. No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene, 10: 785-788, 1995.
43. INK4 expression is frequent in high grade gliomas. Cancer Res., 55: 1941-1945, 1995.
44. Merio, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
45. INK4 protein induction by 5-aza2′deoxycytidine. Oncogene, 10: 1211-1216, 1995.
46. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Turnout, J. M., and Jones, P. A. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
47. Yeager, T., Stadler, W., Belair, C., Puthenveettil, J., Olopade, O., and Reznikoff, C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res., 55: 493-497, 1995.
48. Yarbrough, W., Aprelikova, O., Pei, H., Olshan, A., and Liu, E. Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J. Natl. Cancer Inst., 88: 1489-1491, 1996.